
SKIN Stock Forecast & Price Target
SKIN Analyst Ratings
Bulls say
The Beauty Health Company has demonstrated a strong performance with a fourth-quarter revenue of $96.8 million, exceeding previous estimates and indicating positive momentum in the market. A notable 20% quarter-over-quarter growth in average selling price (ASP) of total systems to $28.8K is attributed to an increased proportion of direct sales, enhancing profitability. Despite being back-end weighted, the encouraging EBITDA guidance and revenue upside driven by consumables signify a robust outlook for the company's future financial performance.
Bears say
The Beauty Health Company's performance has raised concerns, particularly with new placements of core delivery systems declining over 30% year-over-year and quarter-over-quarter, falling significantly short of prior estimates. This slowdown in new system placements threatens future consumables sales, crucial for achieving the company's profitability goals in 2024, especially given that management has provided lower-than-expected first-quarter sales and adjusted EBITDA guidance. Additionally, significant risks including brand integrity, macroeconomic conditions impacting consumer spending, and challenges in the Syndeo upgrade cycle further complicate the company's outlook and undermine its growth potential.
This aggregate rating is based on analysts' research of The Beauty Health Company and is not a guaranteed prediction by Public.com or investment advice.
SKIN Analyst Forecast & Price Prediction
Start investing in SKIN
Order type
Buy in
Order amount
Est. shares
0 shares